Stereotactic body radiotherapy in the treatment of adrenal metastases

Kamran A. Ahmed, Brandon M. Barney, O. Kenneth Macdonald, Robert C. Miller, Yolanda Isabel Garces, Nadia N Laack, Michael Haddock, Robert L. Foote, Kenneth R. Olivier

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3%) were evaluable for local control (LC). The crude LC rate was 100%, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9% and 55%, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.

Original languageEnglish (US)
Pages (from-to)509-513
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume36
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Radiosurgery
Neoplasm Metastasis
Therapeutics
Adrenal Glands
Nausea
Colon
Urinary Bladder
Kidney
Lung
Skin
Survival
Liver

Keywords

  • Adrenal metastases
  • Intensity-modulated radiotherapy
  • Stereotactic body radiation therapy
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Stereotactic body radiotherapy in the treatment of adrenal metastases. / Ahmed, Kamran A.; Barney, Brandon M.; Macdonald, O. Kenneth; Miller, Robert C.; Garces, Yolanda Isabel; Laack, Nadia N; Haddock, Michael; Foote, Robert L.; Olivier, Kenneth R.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 36, No. 5, 10.2013, p. 509-513.

Research output: Contribution to journalArticle

Ahmed, Kamran A. ; Barney, Brandon M. ; Macdonald, O. Kenneth ; Miller, Robert C. ; Garces, Yolanda Isabel ; Laack, Nadia N ; Haddock, Michael ; Foote, Robert L. ; Olivier, Kenneth R. / Stereotactic body radiotherapy in the treatment of adrenal metastases. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2013 ; Vol. 36, No. 5. pp. 509-513.
@article{b0b83fcde6e14ee7ae5a57085e117661,
title = "Stereotactic body radiotherapy in the treatment of adrenal metastases",
abstract = "OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3{\%}) were evaluable for local control (LC). The crude LC rate was 100{\%}, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9{\%} and 55{\%}, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.",
keywords = "Adrenal metastases, Intensity-modulated radiotherapy, Stereotactic body radiation therapy, Stereotactic radiosurgery",
author = "Ahmed, {Kamran A.} and Barney, {Brandon M.} and Macdonald, {O. Kenneth} and Miller, {Robert C.} and Garces, {Yolanda Isabel} and Laack, {Nadia N} and Michael Haddock and Foote, {Robert L.} and Olivier, {Kenneth R.}",
year = "2013",
month = "10",
doi = "10.1097/COC.0b013e3182569189",
language = "English (US)",
volume = "36",
pages = "509--513",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Stereotactic body radiotherapy in the treatment of adrenal metastases

AU - Ahmed, Kamran A.

AU - Barney, Brandon M.

AU - Macdonald, O. Kenneth

AU - Miller, Robert C.

AU - Garces, Yolanda Isabel

AU - Laack, Nadia N

AU - Haddock, Michael

AU - Foote, Robert L.

AU - Olivier, Kenneth R.

PY - 2013/10

Y1 - 2013/10

N2 - OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3%) were evaluable for local control (LC). The crude LC rate was 100%, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9% and 55%, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.

AB - OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3%) were evaluable for local control (LC). The crude LC rate was 100%, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9% and 55%, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.

KW - Adrenal metastases

KW - Intensity-modulated radiotherapy

KW - Stereotactic body radiation therapy

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84885018340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885018340&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182569189

DO - 10.1097/COC.0b013e3182569189

M3 - Article

C2 - 22781389

AN - SCOPUS:84885018340

VL - 36

SP - 509

EP - 513

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 5

ER -